The results of the various programs in international collaboration with Europe and the European Commission, in which the Fonds de recherche du Québec – Santé (FRQS) is a partner, are now revealed. Within the framework of the joint transnational calls launched in 2022, three (3) programs have seen results in the following areas: Neuroscience, Rare Diseases, and Personalized Medicine.

Name of the candidateInstitutionTitle of the project
ERA-NET NEURON (JTC 2022) – Neuroscience Network
Mindy LevinMcGill UniversityComparative study of the mechanism of action of Dry Needling and Botulinum Toxin type A as a treatment for lower limb post-stroke spasticity: a proof of concept controlled trial (STROKE-POC)
Ravi RungtaUniversité de MontréalMICROglia as modulators of brain BLEEDs (MICROBLEEDs)
ERA-NET ERAPerMed (JTC2022) – Personalized Medicine.Network
François-Michel BoisvertUniversité de SherbrookeUrine biomarkers for bladder cancer initial detection and surveillance: a multicentric study to assess the diagnostic accuracy of a comprehensive tool (UBIOBCA)
EJP RD (JTC 2022) – Rare Diseases Network
Arnaud DroitUniversité LavalDevelopment of diagnostic solutions for neurodevelopmental disorders caused by ubiquitin-proteasome system dysfunction  (UPS-NDDiag)
*EJP RD is a partnership program offered in co-funding with CIHR
Total contribution of the FRQS1.12 M$

For any additional information, you can contact:

Maxime Beaudoin
Programs Manager
514 873-2114 EXT 4369